Sobi publishes Q4 and FY 2021 report
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announces its results for the fourth quarter and full year of 2021. October – December 2021 · Total revenue SEK 4,896 M (4,581), +7 per cent, +9 per cent at constant exchange rates (CER) · Haematology revenue SEK 2,242 M (2,081), +8 per cent at CER of which Elocta® SEK 1,063 M (1,071), unchanged at CER, Alprolix® SEK 482 M (419), +16 per cent at CER, and Doptelet® SEK 306 M (191), +60 per cent at CER. First shipment of Empaveli™ achieved · Immunology revenue SEK 2,330 M (2,281), +6 per cent at CER of which